AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12047326
Drug: 3-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day triple therapy for H. pylori eradication
Trial: 12047326
Drug: 7-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day triple therapy for H. pylori eradication
Trial: 12047326
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori stool antigen before therapy
Trial: 12047326
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori stool antigen after therapy
Trial: 9989681
Drug: 1 MJ
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 MJ (340 mL) alcohol (wine or beer)
Trial: 9989681
Drug: fat (cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fat (cream fruit juice), protein (protein fruit juice), carbohydrate (grape juice)
Trial: 8216442
Drug: Glimepiride (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (0.25 mg)
Trial: 8216442
Drug: Glimepiride (0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (0.50 mg)
Trial: 8216442
Drug: Glimepiride (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (1.25 mg)
Trial: 8216442
Drug: Glimepiride (1.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (1.50 mg)
Trial: 3677789
Drug: Combination inhaler
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination inhaler therapy (salbutamol and beclomethasone dipropionate)
Trial: 3677789
Drug: Separate inhaler
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate inhaler therapy (salbutamol and beclomethasone dipropionate)
Trial: 24965573
Drug: Baricitinib (1-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib (1-20 mg single ascending doses, 2-20 mg QD, 5 mg BID for 10 or 28 days)
Trial: 19107071
Drug: N-acetyl-aspartyl glutamic
RxNorm normalized name: acetyl glutamic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-aspartyl glutamic acid (NAAGA) monotherapy over 4 weeks
Trial: 19107071
Drug: Bi-therapy (NAAGA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi-therapy (NAAGA and Levocabastine during the first week, then NAAGA only for the next 3 weeks)
Trial: 11933906
Drug: Prime &
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prime & Bond 2.1 (no D/Sense 2 treatment)
Trial: 11933906
Drug: Bistite II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bistite II SC (no D/Sense 2 treatment)
Trial: 12349021
Drug: Spermicidal preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spermicidal preparations containing nonoxynol-9 (gel products with varying amounts)
Trial: 12349021
Drug: Suppository tablet
RxNorm normalized name: Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppository tablet and film preparation
Trial: 8721468
Drug: i.m. ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. ketorolac (30 mg)
Trial: 8721468
Drug: i.v. ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ketorolac (30 mg)
Trial: 8721468
Drug: intrawound (i.w.)
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrawound (i.w.) ketorolac (30 mg)
Trial: 8721468
Drug: p.o. ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p.o. ketorolac (30 mg)
Trial: 1888644
Drug: Flupirtine 200
RxNorm normalized name: FLUPIRTINE
DrugBank: Flupirtine (DB06623)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupirtine 200 mg administered perorally
Trial: 1888644
Drug: Flupirtine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupirtine (various doses)
Trial: 6356971
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg intramuscular buprenorphine
Trial: 6356971
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intramuscular morphine
Trial: 28842370
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg methylprednisolone acetate (MP)
Trial: 24907224
Drug: Simeprevir (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir (150 mg once daily, orally), peginterferon alfa 2a (180 μg once weekly, subcutaneous injection) or 2b (according to bodyweight), plus ribavirin (1000‐1200 mg/day or 800‐1400 mg/day, orally)
Trial: 24907224
Drug: Placebo (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (once daily, orally), peginterferon alfa 2a or 2b, plus ribavirin
Trial: 22925325
Drug: Probiotics (Lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Lactobacillus GG; ATCC 53103; 1 × 10(10) colony-forming units daily)
Trial: 19757048
Drug: Balsalazide 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balsalazide 3 g/d (n = 38)
Trial: 19757048
Drug: Balsalazide 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balsalazide 3 g/d
Trial: 11435055
Drug: Continuous modified
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous modified glucose-insulin-potassium infusion
Trial: 11435055
Drug: Intermittent intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intravenous (IV) insulin injections
Trial: 9526936
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine (300 microg)
Trial: 9526936
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) clonidine (300 microg)
Trial: 464807
Drug: Doxycycline hyclate
RxNorm normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline hyclate 100 mg twice daily on postoperative days 5 through 10 and then 100 mg daily for six weeks
Trial: 27914210
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy (OIT) using egg
Trial: 22201659
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention started at the beginning of chemotherapy (EE)
Trial: 22201659
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention started at the completion of chemotherapy (CE)
Trial: 19502623
Drug: Warfarin use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin use in patients with AF at discharge
Trial: 19502623
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation therapy at discharge
Trial: 19502623
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy among patients with coronary stents
Trial: 19502623
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation in patients at highest risk of stroke (CHADS(2) score >=2)
Trial: 9673431
Drug: Amlodipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (2.5 or 5 mg once daily)
Trial: 3293372
Drug: Single bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus (150 ml or 175 ml depending on weight)
Trial: 3293372
Drug: Split bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split bolus (first bolus 100 or 125 ml, second bolus 50 ml)
Trial: 3293372
Drug: Bolus-drip (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus-drip (initial bolus 100 or 125 ml followed by rapid IV drip infusion of 50 ml)
Trial: 30260268
Drug: Zolpidem 5
RxNorm normalized name: zolpidem 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 5 mg for 7 days
Trial: 26289557
Drug: Control (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (conventional anti-HF therapies)
Trial: 21843876
Drug: argon laser
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: argon laser trabeculoplasty (ALT) after topical betaxolol hydrochloride treatment
Trial: 11182175
Drug: Telmisartan 10
RxNorm normalized name: telmisartan 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 10 mg once daily
Trial: 11182175
Drug: Telmisartan 20
RxNorm normalized name: telmisartan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 20 mg once daily
Trial: 9156375
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution (45 micrograms nicotine base/kg)
Trial: 9156375
Drug: Intravenous nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous nicotine (15 micrograms nicotine base/kg)
Trial: 25145781
Drug: Tacrolimus +
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus + Wuzhi capsules (WZC) + corticosteroids
Trial: 22205241
Drug: 800 MBq
RxNorm normalized name: dotatate
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 MBq I‐131 (low dose)
Trial: 22205241
Drug: 3700 MBq
RxNorm normalized name: dotatate
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3700 MBq I‐131 (high dose)
Trial: 21147441
Drug: Ajmaline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ajmaline (1 mg/kg) infused at 1 mg/sec
Trial: 21147441
Drug: Ajmaline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ajmaline (1 mg/kg) infused over 10 minutes
Trial: 21147441
Drug: Rapid infusion
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid infusion rate (assessed retrospectively during 386 challenges)
Trial: 21147441
Drug: Slow infusion
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow infusion rate (assessed during the study)
Trial: 21147441
Drug: Rapid infusion
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid infusion rate (assessed during the study)
Trial: 18056188
Drug: High-dose glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose glucocorticoid therapy
Trial: 16265847
Drug: Continuous axillary
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous axillary brachial plexus block with 10 ml 0.75% ropivacaine loading dose followed by 4-5 ml per hour infusion for up to three days (Group A)
Trial: 12410195
Drug: 1% Permethrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Permethrin Creme Rinse (1% PLT) with adjunctive combing
Trial: 9857653
Drug: Bronchoalveolar lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchoalveolar lavage (BAL) mast cell analysis using Carnoy's solution as a fixative and 0.5% solution of Toluidine blue for staining.
Trial: 27539
Drug: Clobazam (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam (30 to 40 mg/day in three divided doses)
Trial: 27539
Drug: Diazepam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (15 to 20 mg/day in three divided doses)
Trial: 31883327
Drug: Fosfomycin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin (4 g dose intravenously 3 hours before catheter placement and removal)
Trial: 30728754
Drug: Location of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Location of hormone replacement therapy
Trial: 16678550
Drug: Fluvoxamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (50 mg for 2 days, then two 50 mg doses 12 hours apart for 5 days)
Trial: 11786648
Drug: DAG (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAG (20 g daily for 12 weeks)
Trial: 11786648
Drug: TAG (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAG (20 g daily for 12 weeks)
Trial: 8133022
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg amlodipine taken in the morning
Trial: 8133022
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg amlodipine taken in the evening
Trial: 8133022
Drug: Medication-Event-Monitoring System
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Medication-Event-Monitoring System (MEMS)
Trial: 8133022
Drug: Days with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days with missed medication removed from analysis
Trial: 3499896
Drug: Antimotion sickness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimotion sickness medications scopolamine:d‐amphetamine (0.4:5.0 mg)
Trial: 3499896
Drug: Promethazine:ephedrine (25:60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine:ephedrine (25:60 mg)
Trial: 3499896
Drug: Naproxyn (275
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxyn (275 or 550 mg)
Trial: 30950739
Drug: Short-term intensive
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term intensive voice therapy (IVT)
Trial: 30950739
Drug: Group IVT
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group IVT (IVT-G)
Trial: 30950739
Drug: Long-term traditional
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term traditional voice therapy (TVT)
Trial: 26672793
Drug: Integrated intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated intervention (cognitive behavioural therapy)
Trial: 24508419
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec (IDeg) at a fixed dose level of 0.6 U/kg for 6 days
Trial: 24508419
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir at a fixed dose level of 0.6 U/kg for 6 days
Trial: 14655848
Drug: Combined Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Group Psychoeducation and Fluoxetine (GPF)
Trial: 7951808
Drug: Homemade cereal‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homemade cereal‐based oral rehydration therapy (HC‐ORT, n = 103)
Trial: 7951808
Drug: Glucose‐based oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose‐based oral rehydration solution (G‐ORS, n = 98)
Trial: 7951808
Drug: Cereal‐based oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cereal‐based oral rehydration solution (C‐ORS, n = 90)
Trial: 3311117
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg salbutamol
Trial: 3311117
Drug: 1.6 mg
RxNorm normalized name: menthol 1.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 mg salbutamol
Trial: 3311117
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg salbutamol
Trial: 21682757
Drug: LB03002 (sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB03002 (sustained-release recombinant growth hormone) for 12 months
Trial: 21682757
Drug: LB03002 (sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB03002 (sustained-release recombinant growth hormone)
Trial: 20172051
Drug: CeO(2) nanoparticles;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CeO(2) nanoparticles; intraperitoneal injections before radiation exposure.
Trial: 18343738
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy combined with probiotics
Trial: 18343738
Drug: Alternative therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative therapeutic options (immunotherapy, ion-exchange resins, new drugs)
Trial: 16319952
Drug: Carmustine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carmustine (300 mg/m2) + Melphalan (200 mg/m2)
Trial: 11052393
Drug: Individually tailored
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually tailored sensory and coping information about analgesic side effects
Trial: 11127439
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor treatment started 3.2 ± 1.7 hours after MI
Trial: 1575341
Drug: 26-G needle
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 26-G needle
Trial: 1575341
Drug: 27-G needle
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 27-G needle
Trial: 23689708
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate (ZnSO4) 125 mg daily for 14 days
Trial: 10893655
Drug: Solid paracetamol
RxNorm normalized name: Corydalis solida whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid paracetamol
Trial: 1333637
Drug: heparin 5000
RxNorm normalized name: HEPARIN 5000 UNT/ML SYRINGE 1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heparin 5000 IU and dihydroergotamine 0.5 mg 8 h‐1
Trial: 1333637
Drug: dextran 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dextran 500 ml 12 h‐1 on the day of surgery and 500 ml on days 1, 3, and 5 postoperatively
Trial: 6368776
Drug: Intermittent lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent lipid infusion (8 hours/day)
Trial: 6368776
Drug: Continuous lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous lipid infusion (24 hours/day)
Trial: 28742409
Drug: 1000 IU
RxNorm normalized name: D 1000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 IU vitamin D3 plus 1000 mg evening primrose oil (EPO)
Trial: 24952576
Drug: Concentrated Triglyceride
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated Triglyceride (rTG) fish oil: EPA of 650 mg, DHA of 450 mg
Trial: 24952576
Drug: Ethyl Ester
RxNorm normalized name: Amben ethyl ester
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethyl Ester (EE) fish oil: EPA of 756 mg, DHA of 228 mg
Trial: 24952576
Drug: Triglyceride (TG)
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglyceride (TG) salmon oil: EPA of 180 mg, DHA of 220 mg
Trial: 24952576
Drug: Phospholipid (PL)
RxNorm normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phospholipid (PL) krill oil: EPA of 150 mg, DHA of 90 mg
Trial: 16158737
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment including complex physical factors (CAP‐ELM‐01)
Trial: 14703267
Drug: Alternative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative treatment models for homeless individuals with severe mental illness; details on dosage and duration not available.
Trial: 1948658
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg intravenous methylprednisolone before ECMO
Trial: 30918434
Drug: Khubchandani's procedure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Khubchandani's procedure with stapled posterior rectal wall resection (group A)
Trial: 28742515
Drug: Paracetamol as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol as adjunct analgesia
Trial: 25846577
Drug: Add-on exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Add-on exenatide twice daily
Trial: 21864718
Drug: Culturally appropriate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally appropriate, group-based behavioral and social support intervention including 16 weekly group sessions and 8 weeks of telephone maintenance counseling.
Trial: 21864718
Drug: Minimal intervention
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal intervention control group receiving 16 weekly health education mailings.
Trial: 17555707
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral group program for spouses of stroke patients (15 bi-monthly 1.5 hour sessions)
Trial: 15776275
Drug: Carbamazepine 200
RxNorm normalized name: carbamazepine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine 200 mg/day for 6 days
Trial: 11919661
Drug: Buprenorphine 2
RxNorm normalized name: buprenorphine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 2 mg daily